Key Takeaways for California Dentists
-
California dentists face a uniquely complex 2026 decision between DSO and private sales because of premium valuations, intense DSO competition, and new regulations effective January 1, 2026.
-
DSO sales typically offer higher headline multiples (4x–9x EBITDA) and often include 5-year employment commitments, 10–30% equity rollover, and earnouts. Private sales usually provide 100% cash at close with a clean 30–90 day exit.
-
SB 351 and the May 2026 ADMI settlement create strict new limits on DSO operations in California, which can reshape deal structures, management fees, and contract enforceability.
-
Real after-tax economics can differ significantly. A $2.4 million DSO offer may yield about $1.68 million cash at close plus illiquid equity, while a $1.5 million private sale delivers full cash certainty. Modeling over 3-, 5-, and 7-year horizons can be one of the main tools for comparison.
-
McLerran & Associates provides side-by-side valuations and buyer vetting to help protect legacy and staff. Schedule a free, confidential discovery call to see which path may fit your practice.
How DSO and Private Sales Differ for California Practices
A DSO sale in California affiliates your practice with a Dental Service Organization that pays an EBITDA-based multiple. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a measure of operating profit. These deals typically include a mix of cash at close, rollover equity, and earnouts, plus a minimum five-year employment commitment.
A private sale transfers the practice to another dentist for roughly 65–85% of collections. These deals are usually 100% cash at close with a 30–90 day transition.
The table below compares the two paths on key metrics. Valuation basis and cash-at-close figures come from multiple industry sources and represent ranges, not guarantees for any specific practice.
|
Metric |
DSO Sale |
Private Sale |
|---|---|---|
|
Valuation Basis |
EBITDA multiple, typically 4x–9x for general dentistry depending on practice scale |
|
|
Cash at Close |
Portion of total value paid at closing, with the balance in equity and earnouts |
100% of deal value (typically SBA-financed) |
|
Work-Back Period |
Minimum five-year employment agreement |
30–90 day transition |
|
Post-Sale Obligations |
Equity rollover, earnouts, and employment terms |
None, which allows a clean exit |
Headline multiples tell only part of the story. A clear comparison usually requires modeling after-tax cash over several years, which can be difficult to run alone. This type of side-by-side modeling sits at the core of McLerran & Associates’ process.
California’s Legal Landscape: SB 351 and Corporate Practice Rules
California’s rules for dental practice ownership are among the most restrictive in the country, and they changed significantly in 2026. Every doctor considering a DSO affiliation in California benefits from understanding three main layers of law.
The Corporate Practice Doctrine. Under California Business and Professions Code §1625, managing a place where dental operations occur is itself considered the practice of dentistry. Only a licensed dentist or a properly formed dental corporation may own or control a dental practice. Non-dentist entities, including DSO management companies, must structure their arrangements carefully to avoid reserved clinical territory.
SB 351 (Effective January 1, 2026). SB 351 bars private equity groups and hedge funds from controlling clinical judgment in dental practices. It prohibits them from dictating diagnostic tests or referrals, imposing patient quotas, restricting treatment, or owning patient records. The law also voids non-compete and non-disparagement clauses in their provider contracts and grants enforcement authority to the California Attorney General. SB 351 works in tandem with AB 1415, which requires advance notice to the California Office of Health Care Affordability for covered transactions and can delay closings beyond a standard 90-day window.
For sellers, these developments influence which DSO partners remain viable in California, how deal structures must read, and which contract terms likely remain enforceable. An advisor who navigates this landscape daily, such as McLerran & Associates through its Los Angeles office led by Steven Au, can be a key resource. These legal constraints also reshape the financial calculus, which makes the real economics of each path more critical than ever.
The Real Economics: Cash at Close, Equity, and Earnouts
Breaking Down DSO Offers. A DSO deal rarely comes as a single simple number. The standard structure includes a mix of cash at close, rollover equity into the DSO’s holding company parent, and a 1–3 year earnout tied to post-close EBITDA maintenance. It also often includes a working capital adjustment and an indemnification escrow held for a period after closing. Rollover equity, which is the ownership stake the seller retains in the DSO, is typically illiquid for several years until a second exit event. Realized outcomes on rollover dollars have ranged from meaningful growth in successful DSO exits to write-downs or delayed liquidity when platforms underperform.
Breaking Down Private Sales. Private buyer deals are typically 100% cash at close, often via SBA financing, with a brief 30–90 day transition and no earnouts or equity components. The headline price can be lower, while certainty is higher and the exit is straightforward.
A Hypothetical Illustration. Consider a California practice with $2 million in revenue and $400,000 in EBITDA. A DSO offer at 6x EBITDA would produce a $2.4 million headline price, with a portion as cash at close, a portion as rollover equity, and a portion as an earnout contingent on post-close performance. A private buyer offer at 75% of collections would produce $1.5 million as 100% cash at close, with no contingencies and a clean exit within about 90 days. The DSO headline appears higher, while the private sale offers more certainty. Which path fits better can depend on the seller’s tax situation, timeline, and risk tolerance, and that comparison usually benefits from careful modeling.
The California Tax Dimension. California’s state capital gains tax rate, up to 13.3%, can materially affect net proceeds. On a $2.5 million sale, the difference between California’s state tax and a zero-state-tax state can reach $200,000–$350,000. Federal long-term capital gains rates can reach 23.8% (20% plus the 3.8% Net Investment Income Tax) on goodwill proceeds, compared with ordinary income rates up to 37% on post-sale salary. Deal structure and tax planning, and how California’s rules interact with federal treatment, can be worth hundreds of thousands of dollars. Dentists should consult their CPA and legal advisors for guidance specific to their situation.
McLerran & Associates builds multi-year, multi-structure financial forecasts for every client. The firm models real after-tax cash across 3-, 5-, and 7-year horizons so the comparison rests on numbers rather than assumptions.
Decision Framework: Economics, Staff, and Legacy
Practice size and personal goals can be some of the main factors in this decision. The following guidelines reflect general market patterns, not guarantees for any individual practice.
By practice revenue:
-
Under $1.5 million in revenue: DSO interest is limited below this threshold, so a private sale to another dentist is often the most realistic and efficient path.
-
Over $3 million in revenue: The economics of scale often favor a DSO or private equity buyer. The same practice can receive materially different valuations depending on buyer type, and a 40–80% DSO premium over private-buyer pricing is possible at this scale.
-
The $1.5–$3 million middle: This “Venn diagram” zone can support either path. A side-by-side valuation becomes especially useful here, which is where McLerran & Associates’ dual-path capability often provides the most value.
Staff, culture, and your role after the sale:
-
In a DSO deal, the seller usually signs a 3–5 year working agreement and shifts from owner to clinical associate. Post-acquisition compensation often moves to 25–30% of collections, compared with the 35–45% effective rate many owners earned through distributions. The right DSO can provide meaningful infrastructure relief in areas like HR, payroll, billing, compliance, and marketing, which can free the doctor to focus on patient care. The wrong fit can create a difficult post-close environment. SB 351 voids non-compete and non-disparagement clauses in DSO provider contracts, yet employment and equity terms remain contractual, so exit clauses need to be negotiated before signing.
-
In a private sale, the seller usually works back only 4–8 weeks and then exits. The buyer is another dentist who often wants to preserve the practice’s culture, patient relationships, and staff. Private buyer deals typically pay 100% of the agreed price at closing with no performance contingencies.
Key questions to consider:
-
How long do you want to keep working after the sale?
-
How much cash do you prefer at close compared with potential future upside?
-
How comfortable are you with equity that may remain illiquid for several years?
-
How much weight do you place on clinical autonomy and practice culture after the transition?
-
What does your staff need from this transition to feel secure?
McLerran & Associates optimizes for both price and fit. The firm vets buyers to help protect the practice’s legacy, staff, and patients, and serves as a buffer that supports goodwill throughout the process. Poorly run DSOs with difficult post-close reputations are excluded from consideration.
Because McLerran & Associates runs both paths in roughly equal measure, with approximately 2,000 completed sales, about $2 billion in closed transaction volume, and more than 10,000 practices evaluated, the firm can produce a true side-by-side valuation. Owners then choose with fuller information. The firm’s transaction rate of approximately 85–90% compares with an industry norm closer to 35–40%, and clients often achieve materially higher valuations than owners who sell on their own.
Schedule a free, confidential discovery call with McLerran & Associates and find out what your practice may be worth in both markets. Call (512) 900-7989 or email info@dentaltransitions.com.
Frequently Asked Questions
What is the 50-40-30 rule in dentistry?
The 50-40-30 rule is a dental industry overhead benchmark. Overhead should not exceed 50% of collections for a solo practice, 40% for a small group, and 30% for a mature DSO platform. This rule serves as a guideline for operational benchmarking, not as a valuation formula.
Practice valuation depends on EBITDA, collections, buyer type, practice scale, and market conditions. A practice that fits the 50-40-30 guideline may still sell at a wide range of multiples based on those variables. Owners usually benefit from avoiding this rule as a pricing shortcut and instead using a comprehensive, CPA-led EBITDA analysis.
Can I back out of a DSO contract in California?
Exit rights depend on the specific contract terms negotiated before signing. SB 351, effective January 1, 2026, voids non-compete and non-disparagement clauses in DSO provider contracts in California, which provides meaningful protection. Employment agreements, equity rollover terms, and earnout provisions still function as binding obligations.
Sellers who want the option to exit early usually need those provisions written into the agreement before the letter of intent is signed. Exit structures vary widely across DSO buyers, and an experienced advisor can help identify buyers with more flexible terms and negotiate on the seller’s behalf.
How long does a DSO sale take in California?
A typical DSO sale process in California can run about 45–60 days for the competitive bid phase and 60–120 days for due diligence and closing, for roughly 4–6 months from engagement to close. Many sources report 6–12 months for the full process, depending on practice readiness and whether a matched buyer is used.
California’s AB 1415 adds a mandatory 90-day advance notice requirement to the California Office of Health Care Affordability for covered transactions, which can extend timelines further if a cost and market impact review begins. Private sales typically close in 90–150 days. Sellers benefit from planning for California-specific regulatory steps that do not apply in many other states.
How much cash will I actually receive at close?
In a DSO deal, the total value usually splits between cash at close, rollover equity that may remain illiquid for several years, and earnouts that depend on post-close performance. In a private sale, the buyer typically pays 100% of the agreed price at close, often through SBA financing, with no earnouts or equity components.
The trade-off often comes down to headline price versus certainty. A DSO deal can carry a higher headline number, while the seller’s realized cash over time depends on earnout achievement, equity performance, and tax treatment. Modeling these outcomes over a 3-, 5-, and 7-year horizon, after California’s state capital gains tax and federal rates, can be one of the most reliable ways to compare the two paths on equal terms.
